Post Reply
1601-1620 of 2385
divident is 0.27 cent?? when payable???
Healthway’s 4Q09
net profit of S$3.1m
(+35% YoY) was
in line with
our expectations. This was largely attributed to the maiden full year
contribution from its acquisition of
several practices in
mid-08, organic growth
at its medical centres and
the expansion of
its clinic network
during the year.
A dividend of 0.24
S¢ per share for FY09 was declared. It recently placed out 108m shares to IFC and secured a US$15m loan from IFC. At the same time, it also placed
out 85.9m shares
to major shareholders. This would allow it to raise ~S$45m, the bulk of which would be used to fund
its China expansion plans. We maintain our BUY recommendation, but
we have raised
our TP to
S$0.26 (previously S$0.21), taking into account
the potential growth
that the new
clinics can generate, despite an
enlarged share base. Balance sheet is healthy. As at end 4Q09, Healthway’s net
gearing stands at 0.2x. In order to fund its China expansion plans, we do not
rule out further fund raising activity.
Healthway can
potentially open another
30 medical centres
in China. It plans
to open another
6 medical centres
in Shanghai in
FY10. Our previous report had assumed that Healthway
did not use any of the additional funds (from the placements
and loan). Here,
we assume that
majority of these
funds are used for its expansion
in China. Healthway had budgeted S$20m
for Phase 1 of its expansion, leaving
it with ~S$25m from the
fund raising. We
estimate that Healthway can
possibly open at least another 30 medical centres over the next five years
(or 6 new
centres a year).
This would fuel
earnings growth going forward.
TP raised to
S$0.26. Based on our DCF approach, we arrive at a TP of S$0.26, supported by
the contribution from
its potential new
medical centres in China from FY11, while keeping its Singapore
expansion plans intact. Maintain BUY.
Article reproduced
from DMG Partners dated 8th March 2010
To summarize
FYE 31 Dec (S$m) FY07 FY08 FY09 FY10F FY11F
Turnover 42.8 80.9 98.6 128.9 216.7
Net Profit 5.6 9.6 15.2 17.7 26.3
% chg YoY n.a. 70.6% 59.5% 16.3% 48.2%
EPS (S¢) 402.2 1.3 1.1 1.0 1.4
DPS (S¢) - 0.1 0.1 0.2 0.3
Div Yield - 0.7% 0.7% 1.1% 1.7%
ROE 87.2% 7.1% 10.2% 8.6% 11.1%
ROA 5.4% 4.3% 6.6% 5.7% 7.6%
P/E (x) 0.0 12.7 15.0 16.5 11.8
P/B (x) 0.0 1.7 1.6 1.5 1.3
Source: Company and DMG Estimates
I like to take you pple thru history again
On 4th January was when DMG issued the 1st call of TP 28 cents
Below was their statement, I quote, unquote
Healthway Medical: S$0.135
BUY (TP: S$0.28)
The giant stirs
Starting out in 1990, Healthway Medical has grown to be Singapore’s largest
clinic operator, boasting 90 clinics across the island. It has drawn out
aggressive plans to grow its China business, a market that the management
is intimately familiar with, having been there for the past few years.
Despite its size and clout, it is one of the most attractively priced
healthcare services player listed in Singapore, trading at a mere 12x
forward P/E which is lower than the industry average of 19.5x. Initiate
coverage with BUY and target price of S$0.28.
Expanding into China; Demand for private healthcare in China is expected to
rise, given increasingly affluent but ageing population. Its maiden foray
into China was through a convertible loan agreement with Crane Medical.
Healthway intends to expand in China in a big way, starting with a S$20.0m
investment in the first phase, with plans to grow from two medical centres
in Shanghai, to eight within the year. We believe China would become a
significant growth driver for the Group.
Not resting on its laurels in Singapore. Healthway continues to strengthen
its position in Singapore. It has expanded its NeuGLOW aesthetics medical
centres and opened up more channels for growth in specialist healthcare
services (though establishing new eye, ENT and surgery centres). Healthway
will be opening more specialist centres (for dental, heart and child
development) in 1Q10. This places it in a good position to ride on the
recovery of the medical tourism industry in Singapore.
Healthy balance sheet supports potential M&A. Balance sheet is healthy,
with a net gearing of 0.2x as at end 3Q09. Coupled with stable cash flows
from its operations, we think that Healthway has the capability to take on
strategic investments to continue growing its operations.
Initiate with BUY, target price of S$0.28. Assuming a WACC of 8.5%, we
arrive at a target price of S$0.28, which implies a forward P/E of 25x.
Healthway currently trades at an attractive P/E of 12.1x FY10 earnings.
On that day 4th January 2010
O 0.14, H 0.16, L 0.135, C 0.16
The following day, 5th January 2010
O 0.165, H 0.17, L 0.16, C 0.16
Within a few days, on the 8th January 2010
O 0.19, H 0.195, L 0.185, C 0.185
I am not asking people to focus on the TP
Everyone has a TP, even you and I have a TP
You ask the taxi driver who fetch you this morning, he has TP
But I am asking you to focus on the magnitude of the rise in share price after this announcement and draw your own conclusions
Wonderful! Such a good news to all shareholders. Let's hope it keep on moving... steadily... Thank you.
newbiestock ( Date: 08-Mar-2010 14:22) Posted:
A good friend send the report to my email, so I don't have the link but i have uploaded it to yousendit.
Click the link to download and read the report yrself. Note: this link is valid for 7 days.
https://www.yousendit.com/download/THE3TkFwTlF0TW14dnc9PQ
NOTE: Analyst reports are just there to serve for a reference guide ONLY.
Cheers
wangwang828 ( Date: 08-Mar-2010 14:14) Posted:
oh really?? I'm glad to hear that... Thanks for the update. Btw, where you view their latest report? |
|
|
|
A good friend send the report to my email, so I don't have the link but i have uploaded it to yousendit.
Click the link to download and read the report yrself. Note: this link is valid for 7 days.
https://www.yousendit.com/download/THE3TkFwTlF0TW14dnc9PQ
NOTE: Analyst reports are just there to serve for a reference guide ONLY.
Cheers
wangwang828 ( Date: 08-Mar-2010 14:14) Posted:
oh really?? I'm glad to hear that... Thanks for the update. Btw, where you view their latest report?
newbiestock ( Date: 08-Mar-2010 14:04) Posted:
wangwang828,
New DMG analyst report today on 8th March just re-rated Healthway to a target price of 26 cents from 21 cents, after factoring into the potential growth of the new clinics.
I just received the new report... |
|
|
|
oh really?? I'm glad to hear that... Thanks for the update. Btw, where you view their latest report?
newbiestock ( Date: 08-Mar-2010 14:04) Posted:
wangwang828,
New DMG analyst report today on 8th March just re-rated Healthway to a target price of 26 cents from 21 cents, after factoring into the potential growth of the new clinics.
I just received the new report...
wangwang828 ( Date: 05-Mar-2010 10:38) Posted:
Hi pharoah88,
It HW possible to hit 0.195 ? |
|
|
|
wangwang828,
New DMG analyst report today on 8th March just re-rated Healthway to a target price of 26 cents from 21 cents, after factoring into the potential growth of the new clinics.
I just received the new report...
wangwang828 ( Date: 05-Mar-2010 10:38) Posted:
Hi pharoah88,
It HW possible to hit 0.195 ?
pharoah88 ( Date: 05-Mar-2010 09:23) Posted:
Friday, 5 March 2010
09:03.49 S$0.165 BOUGHT from BUYER 3,088,000
CLEAN SWEEP FiRST THiNG iN the mOrning.
4,232,000 bought yesterday at S$0.160 can nOw take prOfit.
Or WAiT fOr S$0.170 tO GAiN HiGHER prOfit. |
|
|
|
Monday, 8th March 2010 12:35pm
13,714,000 BOUGHT from SELLER S$0.170 ~ S$0.175
End Of day CLOSE A$0.180?
S$0.170 CLEANED OUT.
Refer to DRsubaru's FA & TA Analysis belOw.
WHEN PARKWAY takes Over HEALTHWAY,
regrets Regrets REgrets REGrets REGRets REGREts REGRETs REGRETS R E G R E T S
pharoah88 ( Date: 08-Mar-2010 11:19) Posted:
Last CALL for LAST BET
Last CHANCE to BUY at S$0.170 before the MANDATE on Tuesday, 9 March 2010.
EGM The PINES CLUB
|
|
what????
It was just 2.9 million vol a while ago. Suddenly shoot up to 11 million vol transacted... All taken at 17 cents.....................
this counter is crazy...
Now 17.5 cents selling
Which Fund(s) is/are buying Q&M D for what reasons?
Q&M D is beating the price down?
drsubaru ( Date: 05-Mar-2010 17:27) Posted:
Amazing, did you guys see the last minute tussle
Keep trying to close at 17 cents buay sai...
A good fren say will close at 18-18.5 today, I say very difficult.....
Last few days always fight in last 15 minutes
BB have frenly also got unfrenly ones....
I small fry , stay at sideline watch action nia
What is more amazing, did you see Q&M? Sibei action with no good news coming, charts look terrible, price action in clouds, Kijun has cross Tenkan downwards, Chikou span also down and yet still chiong.....
|
|
Last CALL for LAST BET
Last CHANCE to BUY at S$0.170 before the MANDATE on Tuesday, 9 March 2010.
EGM The PINES CLUB
ATTEND the EGM tomorrow at The PINES CLUB.
MEET the people who are PULLING the STORM TUG-Of-WAR
Will a major shareholder STEP IN to deRAIL the MANDATE?
kivine ( Date: 05-Mar-2010 16:43) Posted:
hopefully one that blows us all the way up
newbiestock ( Date: 05-Mar-2010 16:22) Posted:
pharoah88, what type of storm are u expecting??? |
|
|
|
Amazing, did you guys see the last minute tussle
Keep trying to close at 17 cents buay sai...
A good fren say will close at 18-18.5 today, I say very difficult.....
Last few days always fight in last 15 minutes
BB have frenly also got unfrenly ones....
I small fry , stay at sideline watch action nia
What is more amazing, did you see Q&M? Sibei action with no good news coming, charts look terrible, price action in clouds, Kijun has cross Tenkan downwards, Chikou span also down and yet still chiong.....
dr subaru hats off!!
http://i240.photobucket.com/albums/ff80/drsubaru73/2010Mar-HEALTHWAYMEDICALCORPLTDIchi.png
One could see that the last couple of day, there was uncertainty, it was kinda trendless as the price action was within the kumo
But I do believe in the coming days as the price action breaks out of the kumo which it already seems to be doing, together with the price action going above the Tenken and Kijun. we will see better and better days
I hope to see the Tenken cross over the Kijun as well, hopefully within a few days
The Chikou also seems to be trending upwards and hopefully pierces above the price action
The kumo is shaping up nicely and provides support at 0.145 (previously I mention the support is 0.15 and that is not a number pluck out from the sky nor is it a magical number from unknown source
http://i240.photobucket.com/albums/ff80/drsubaru73/2010Mar-HEALTHWAYMEDICALCORPLTDMACD.png
Back to basic, the short MA is crossing over the intermediate one, the 200dMA is nice and low down with plenty of support
The MACD cross is also evident, but hopefully crosses upwards with much more conviction
Praise, drsubaru.
A long essay for us to read. :)
Below is an
analysis of Healthway from the Fundamental and Technical Analysis point of view.
It is written in my personal capacity and is neither an article meant to induce
market movement nor to entice people to trade in whatever directions.
First and
foremost, a fair comparison needs to made with regards to other medical players
in order for the analysis to be adequate. Let’s take a history tour. Healthway
Medical was listed on the catalist board on 4th July 2008. Now many
would ask, why would such a big and exciting entity like HW list on catalist
and not on mainboard? The exposure of a mainboard listing would be so great
compared to catalist with most brokerages and analyst choosing most of the time
to cover a mainboard listing. Well, the simple reason is HW as PROHIBITED FROM
LISTING ON SGX MAINBOARD BECAUSE IT REQUIRES THE ACCOUNTS OF THE LAST 3 YEARS
to be audited by the SAME ACCOUNTANCY FIRM. And one would know that the
acquired entities have accounts maintained by different accounting firms. Yes,
as simple as it can get. HW was following a SGX directive. Fastword to 4th
July 2010, in about 4 months, HW would have fufilled the SGX crieria and an
upgrade to the mainboard is only eminent. It is only a matter of timing. No doubts,
a mainboard does not change a valuation of a company but the greater visibility
not just to the local investors and overseas investor bodes well to the future
of HW. With all due respect to brokege house and analysts, once HW gets
coverage from another 1-2 houses as compared to the current DMG, this would add
upward pressure on the share price. This is all a logical deduction.
Secondly, in the
BT article on 24th Feb, 2010, the soon to be elected CEO of Parkway,
Dr Tan See Leng mentioned “the organic growth is one key pillar although I
wouldn’t rule out some form of M&A”. Now we have to understand here that Dr
Tan See Leng was ex-CEO of HW before they sold off to BUPA. I would like to
extrapolate this info a little further by saying that he has the drive and
gumption to make this M&A happen….
Let’s try to see
what are possible M&A targets? There are few basic assumptions that I would
like to make. The entity has to be a medical player. It most likely is a
strategic partner that complements rather than competes for the same slice of
the pie. It most likely operates in the same strategic sphere of influence and
that means in Asia, so I am excluding USA, EU and Ozzie partners. And
last but not least it must be a company that is growing and can value add to
the exisitng portfolio of their core business. Let’s zoom down on the medical
players in Singapore.
On the surface, immediately, a few are excluded based on their poor strategic
alliance potential and earnings. Pacific Healthcare and Asia Medic is naturally
poor candidates. Raffles Medical is pretty much a competitior and not complemetary at all. Other
smaller and niche players liike Singapore Medical Group, Q&M and TMC are
also poor candidates for a M&A. Over the crossway, Qualitas Medical Group
is listed on SGX and is hardly exciting. In Thailand, Bumrungrad is unlikely to
sell out and after what happen to Shin Corp, there will naturally be some
weariness. If you have been following me so far, there is only 1 logical
deduction what is the potential M&A target. One is the largest private hospital
provide in Asia and the other is the largest GP clinic chain in Singapore with
the largest chain of private paediatric and orthopaedic specialists. The amount
of cross referrals will be tremendous. The common interest in China as an
emerging market is tilted in HW favour. Their latest director is from China and I would naturally deduce that he can
add value to the operation in China.
Some are worried that World Bank does not get the placement shares and what
would happen to the madate on the China expansion of HW. I am of the
opinion that World Bank is probably a passive investor rather than active
ongoing partner who can really help HW expand, so even if the HW deal falls
through, HW can can funding elsewhere. HW already has 2 clinics in China, Shanghai,
Puxi and Pudong district and according to their announcements, are looking
forward to add another 6-8 by the end of the year. This to me is phenomenon. Parkway
paid USD 42 million for World Link to gain a foothold in China (http://www.zoominfo.com/people/Seah_Jonathan_1199331965.aspx)
Now, that was valued
at closed to 50X the PE and that was just for 5 clinics. One must understand
that the entry barrier to the China
healthcare market is not so easy. Why would Raffles Medical Group still be
squatting in Hong Kong after so many year? 10
years ago, they had 1-2 clinics in Hong Kong,
now 10 years later tell me how many clinics do they have. So HW is the
advantage in so many fronts. They did not have to overpay for achieving a
presence in China
and with or without World Bank endorsement, they will definitely march on. They
have the ‘guangxi’ to succeed in the world’s biggest emerging medical industry. First mover
advantage is what HW has, just look at Raffles Medical squatting in HK and you
can appreciate the vast difference in clout they have.So what if Raffles has
GIC/Temasek as a investor, they are not given preference even though Singapore
has SIP and Tianjin Eco Project. I give you an analogy, many years ago, when
Buick and VW moved to China in the early days, they established a foothold that
is still felt to this day and has left the late upstarts like Honda and Toyota clawing
for a piece of the action. Why would Toyota
and Honda being Japan MNCs and linked so close geograhically and with vastly
superior technology compared to the Americans and Europeans not have a distinct
advantage? 1 word ‘guangxi’. In the 19th January press release to
SGX, 6 new medical centres are earmarked to add to the exisiting 2, making a
total of 8 in total by
th end of the year. How many of these 6 are already being planned and at what
stage of development, I do not know. But I would reckon that for a statement to
be made like these and for the World Bank to take a step towards getting a
placement share, these are definite concrete plans and not cheap talk plugged
out of the air.
HW since its
inception is growing from strength to strength. Healthway
Medical’s profit has grown substantially for FY09 (compared to FY08) 59.5%.
And I do feel that at this exciting phase of growth for the company, this could
potentially be duplicated for many years to come when the China growth story
bears fruit. I compared this to Raffles,a mature medical player though being
flushed with cash does not appear at the current moment to have a viable
expansion strategy which is visible. They have 50 plus million which is sitting
there, hopefully some will be returned to shareholders via a special dividend. But
HW has 100 million plus after the rights issue and after a successful placement
hoepfully that can be invested to reap potentially greater benefits that what
Raffles can hope to achieve.
So in summary, HW is poise to really take off and if
the last couple of days of market action is anything to go by, we are in for a
long flight up to space.